BDTX

Black Diamond Therapeutics, Inc. is a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies to treat patients with genetically defined cancers. Headquartered in Cambridge, Massachusetts, Black Diamond has pioneered its proprietary Mutation-Allostery-Pharmacology (MAP) platform to address oncogenic driver mutations that have been historically undruggable. The company's approach involves designing allosteric inhibitors that bind to cancer-causing proteins at sites distinct from their active sites, enabling highly selective targeting of specific mutations while sparing normal proteins. Black Diamond's lead program, BDTX-1535, is an investigational inhibitor designed to target specific HER2 driver mutations found in non-small cell lung cancer and other solid tumors. These HER2 mutations represent oncogenic drivers distinct from HER2 amplification and overexpression (which are targeted by existing HER2 drugs like trastuzumab), requiring mutation-selective inhibitors. The company is conducting clinical trials evaluating BDTX-1535 in patients whose tumors harbor these specific HER2 mutations. The MAP platform has generated additional drug candidates targeting other previously undruggable oncogenic mutations. Black Diamond's precision medicine approach identifies patient populations most likely to benefit from its therapies based on specific genetic alterations in their tumors. This biomarker-driven strategy enables more efficient clinical development and potentially higher response rates compared to non-selected populations. The company addresses significant unmet needs by developing targeted therapies for patients with genetically defined cancers who currently lack effective treatment options. Black Diamond continues advancing its clinical programs while leveraging the MAP platform to expand its pipeline with additional mutation-specific cancer therapies, aiming to transform treatment for patients with previously undruggable mutations.